Multiple Myeloma

Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and manage talquetamab adverse effects, with prior experience from chimeric antigen receptor (CAR) T-cell therapy providing valuable context for understanding potential complications such as cytokine release syndrome (CRS).

Panelists discuss how real-world data consistently show bispecific efficacy matching clinical trial results despite treating higher-risk patients, and how prophylactic interventions have reduced cytokine release syndrome severity.

Panelists discuss how CAR T-cell therapy should generally precede bispecifics when possible due to T-cell exhaustion concerns, though they agree there are virtually no absolute contraindications to bispecific therapy.

Panelists discuss how health care providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from inpatient to outpatient settings, ensuring proper recognition and treatment of adverse effects such as cytokine release syndrome (CRS).

Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.

Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.

Panelists discuss how successful talquetamab treatment requires coordinated care between inpatient and outpatient teams, comprehensive caregiver preparation including education materials and emergency contact information, and access to multidisciplinary health care providers as needed.

Panelists discuss how expectations for treatment outcomes can become more positive over time through experience with multiple therapies, staying informed about clinical trials and new treatments, and focusing on quality of life as a primary treatment goal alongside disease control.

Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.

CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.

Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.

Panelists discuss how caregivers can navigate the initial shock of a myeloma diagnosis by seeking reliable information from trusted medical websites, connecting with local support groups, and accessing resources from organizations such as the International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF), and patient advocacy groups.

Panelists discuss how Alan Plisskin's multiple myeloma diagnosis began with severe back and hip pain, progressed through life-threatening complications, including seizures and vocal cord paralysis, and revealed extensive lytic lesions throughout his body that required immediate intensive treatment.

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.

Phase 1b/2 BGB-11417-105 trial data showed low rates of high-grade infection and hematologic toxicity with sonrotoclax-based therapy in multiple myeloma.

Belantamab mafodotin plus lenalidomide and dexamethasone yielded a stringent CR of 42.9% in patients with newly diagnosed multiple myeloma.

Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.

Iberdomide with daratumumab and dexamethasone led to an ORR of 93.1%, with stringent CRs in 30.1%, in those with newly diagnosed multiple myeloma.

Data from the TANDEMM trial show enduring responses with concurrent anti-GPRC5D and anti-BCMA therapy in relapsed/refractory multiple myeloma.

The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.

As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.

Patients with high-risk multiple myeloma who received BPd maintenance therapy reported no events of progression in the phase 2 trial.

The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.

Treatment with ISB 2001 led to an overall response rate of 74% across dose levels 1 to 9 in patients with relapsed/refractory multiple myeloma.

Adverse effects were manageable when patients with heavily pretreated multiple myeloma were given cevostamab consolidation after receiving CAR T-cell therapy.

MRD-negative remission was achieved in 74.8% of all patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone.

Additional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.